Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells

Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells

Defects in epigenetic pathways are key drivers of oncogenic cell proliferation. We developed a LSD1/HDAC6 multitargeting inhibitor (iDual), a hydroxamic acid analogue of the clinical candidate LSD1 inhibitor GSK2879552. iDual inhibits both targets with IC<sub>50</sub> values of 540, 110,...

Full description

Bibliographic Details
Main Authors:	Ipek Bulut, Adam Lee, Buse Cevatemre, Dusan Ruzic, Roman Belle, Akane Kawamura, Sheraz Gul, Katarina Nikolic, A. Ganesan, Ceyda Acilan
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	Cancers
Subjects:	epigenetics histone deacetylases (HDACs) lysine demethylases (KMDs) multitargeting combination therapy acute myeloid leukemia
Online Access:	https://www.mdpi.com/2072-6694/14/23/6014

Similar Items

Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?
by: Pedro A. Lazo
Published: (2022-08-01)

Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin–HDAC Inhibitor Hybrids as Multitarget Drugs
by: Lukas von Bredow, et al.
Published: (2022-03-01)

SYNTHESIS, LSD1 INHIBITORY ACTIVITY, AND LSD1 BINDING MODEL OF OPTICALLY PURE LYSINE-PCPA CONJUGATES
by: Yukihiro Itoh, et al.
Published: (2014-02-01)

HDAC3 and HDAC8 are required for cilia assembly and elongation
by: Seon-ah Park, et al.
Published: (2019-08-01)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
by: Elizabeth A. Thomas
Published: (2014-05-01)

Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
by: Giorgio Milazzo, et al.
Published: (2020-05-01)

Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6
by: G. R. Vanaja, et al.
Published: (2018-05-01)

New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis
by: Yi Luan, et al.
Published: (2022-04-01)

Knocking down LSD1 inhibits the stemness features of colorectal cancer stem cells
by: J. Chen, et al.

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
by: Christian Mayr, et al.
Published: (2021-07-01)

Effects of novel HDAC inhibitors on urothelial carcinoma cells
by: Aline Kaletsch, et al.
Published: (2018-07-01)

RcLS2F – A Novel Fungal Class 1 KDAC Co-repressor Complex in Aspergillus nidulans
by: Ingo Bauer, et al.
Published: (2020-02-01)

Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer
by: Nikolaos Garmpis, et al.
Published: (2022-10-01)

A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
by: Anna Fontana, et al.
Published: (2022-09-01)

The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus
by: Saikat Dewanjee, et al.
Published: (2021-05-01)

HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements.
by: Michal eMielcarek, et al.
Published: (2015-02-01)

Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells
by: Christian Schrenk, et al.
Published: (2023-03-01)

Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity
by: Hany S. Ibrahim, et al.
Published: (2021-12-01)

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
by: Zizhen Feng, et al.
Published: (2016-03-01)

Chemical modulation of Schistosoma mansoni lysine specific demethylase 1 (SmLSD1) induces wide-scale biological and epigenomic changes [version 1; peer review: 2 approved]
by: Iain W. Chalmers, et al.
Published: (2023-03-01)

Role of HDACs in normal and malignant hematopoiesis
by: Pan Wang, et al.
Published: (2020-01-01)

LSD1: Expanding Functions in Stem Cells and Differentiation
by: Carlos Martinez-Gamero, et al.
Published: (2021-11-01)

HAT- and HDAC-Targeted Protein Acetylation in the Occurrence and Treatment of Epilepsy
by: Jie Wang, et al.
Published: (2022-12-01)

Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy
by: Maria Gkotzamanidou, et al.
Published: (2021-09-01)

Tau-dependent HDAC1 nuclear reduction is associated with altered VGluT1 expression
by: Giacomo Siano, et al.
Published: (2023-05-01)

The Catalytic-Dependent and -Independent Roles of Lsd1 and Lsd2 Lysine Demethylases in Heterochromatin Formation in <i>Schizosaccharomyces pombe</i>
by: Bahjat F. Marayati, et al.
Published: (2020-04-01)

Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
by: Julia Krushkal, et al.
Published: (2024-12-01)

Integrated Analysis Reveals the Potential Significance of HDAC Family Genes in Lung Adenocarcinoma
by: Congkuan Song, et al.
Published: (2022-08-01)

Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients
by: Li Ma, et al.
Published: (2020-09-01)

LSD1 in beige adipocytes protects cardiomyocytes against oxygen and glucose deprivation
by: Yiqiu Cao, et al.
Published: (2023-01-01)

Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity
by: Salma Darwish, et al.
Published: (2022-07-01)

HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities
by: Emily Koeneke, et al.
Published: (2015-04-01)

Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib
by: Yi Zong, et al.
Published: (2024-03-01)

Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells
by: Yingjun Li, et al.
Published: (2022-07-01)

Increased Abundance of Nuclear HDAC4 Impairs Neuronal Development and Long-Term Memory
by: Patrick Main, et al.
Published: (2021-03-01)

Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers
by: Dong Yeul Lee, et al.
Published: (2023-02-01)

Fungal Lysine Deacetylases in Virulence, Resistance, and Production of Small Bioactive Compounds
by: Ingo Bauer, et al.
Published: (2021-09-01)

Myocyte-specific overexpressing HDAC4 promotes myocardial ischemia/reperfusion injury
by: Ling Zhang, et al.
Published: (2018-07-01)

The Epigenetic Controller Lysine-Specific Demethylase 1 (LSD1) Regulates the Outcome of Hepatitis C Viral Infection
by: Georgia Papadopoulou, et al.
Published: (2023-11-01)

Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
by: Qian Zhao, et al.
Published: (2022-08-01)